Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Identifieur interne : 003688 ( Ncbi/Merge ); précédent : 003687; suivant : 003689Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.
Auteurs : Andrea Cipriani [Royaume-Uni] ; Xinyu Zhou [République populaire de Chine] ; Cinzia Del Giovane [Italie] ; Sarah E. Hetrick [Australie] ; Bin Qin [République populaire de Chine] ; Craig Whittington [États-Unis] ; David Coghill [Australie] ; Yuqing Zhang [République populaire de Chine] ; Philip Hazell [Australie] ; Stefan Leucht [Allemagne] ; Pim Cuijpers [Pays-Bas] ; Juncai Pu [République populaire de Chine] ; David Cohen [France] ; Arun V. Ravindran [Canada] ; Yiyun Liu [République populaire de Chine] ; Kurt D. Michael [États-Unis] ; Lining Yang [République populaire de Chine] ; Lanxiang Liu [République populaire de Chine] ; Peng Xie [Australie]Source :
- Lancet (London, England) [ 1474-547X ] ; 2016.
Descripteurs français
- KwdFr :
- Adolescent, Amitriptyline (administration et posologie), Amitriptyline (effets indésirables), Antidépresseurs (administration et posologie), Antidépresseurs (effets indésirables), Calendrier d'administration des médicaments, Chlorhydrate de duloxétine (administration et posologie), Chlorhydrate de duloxétine (effets indésirables), Chlorhydrate de venlafaxine (administration et posologie), Chlorhydrate de venlafaxine (effets indésirables), Citalopram (administration et posologie), Citalopram (effets indésirables), Clomipramine (administration et posologie), Clomipramine (effets indésirables), Désipramine (administration et posologie), Désipramine (effets indésirables), Enfant, Essais contrôlés randomisés comme sujet, Facteurs de confusion (épidémiologie), Fluoxétine (administration et posologie), Fluoxétine (effets indésirables), Humains, Imipramine (administration et posologie), Imipramine (effets indésirables), Miansérine (administration et posologie), Miansérine (analogues et dérivés), Miansérine (effets indésirables), Médecine factuelle, Méthode en double aveugle, Nortriptyline (administration et posologie), Nortriptyline (effets indésirables), Paroxétine (administration et posologie), Paroxétine (effets indésirables), Plan de recherche, Résultat thérapeutique, Sertraline (administration et posologie), Sertraline (effets indésirables), Théorème de Bayes, Triazoles (administration et posologie), Triazoles (effets indésirables), Trouble dépressif majeur (traitement médicamenteux).
- MESH :
- administration et posologie : Amitriptyline, Antidépresseurs, Chlorhydrate de duloxétine, Chlorhydrate de venlafaxine, Citalopram, Clomipramine, Désipramine, Fluoxétine, Imipramine, Miansérine, Nortriptyline, Paroxétine, Sertraline, Triazoles.
- analogues et dérivés : Miansérine.
- effets indésirables : Amitriptyline, Antidépresseurs, Chlorhydrate de duloxétine, Chlorhydrate de venlafaxine, Citalopram, Clomipramine, Désipramine, Fluoxétine, Imipramine, Miansérine, Nortriptyline, Paroxétine, Sertraline, Triazoles.
- traitement médicamenteux : Trouble dépressif majeur.
- Adolescent, Calendrier d'administration des médicaments, Enfant, Essais contrôlés randomisés comme sujet, Facteurs de confusion (épidémiologie), Humains, Médecine factuelle, Méthode en double aveugle, Plan de recherche, Résultat thérapeutique, Théorème de Bayes.
English descriptors
- KwdEn :
- Adolescent, Amitriptyline (administration & dosage), Amitriptyline (adverse effects), Antidepressive Agents (administration & dosage), Antidepressive Agents (adverse effects), Bayes Theorem, Child, Citalopram (administration & dosage), Citalopram (adverse effects), Clomipramine (administration & dosage), Clomipramine (adverse effects), Confounding Factors (Epidemiology), Depressive Disorder, Major (drug therapy), Desipramine (administration & dosage), Desipramine (adverse effects), Double-Blind Method, Drug Administration Schedule, Duloxetine Hydrochloride (administration & dosage), Duloxetine Hydrochloride (adverse effects), Evidence-Based Medicine, Fluoxetine (administration & dosage), Fluoxetine (adverse effects), Humans, Imipramine (administration & dosage), Imipramine (adverse effects), Mianserin (administration & dosage), Mianserin (adverse effects), Mianserin (analogs & derivatives), Nortriptyline (administration & dosage), Nortriptyline (adverse effects), Paroxetine (administration & dosage), Paroxetine (adverse effects), Randomized Controlled Trials as Topic, Research Design, Sertraline (administration & dosage), Sertraline (adverse effects), Treatment Outcome, Triazoles (administration & dosage), Triazoles (adverse effects), Venlafaxine Hydrochloride (administration & dosage), Venlafaxine Hydrochloride (adverse effects).
- MESH :
- chemical , administration & dosage : Amitriptyline, Antidepressive Agents, Citalopram, Clomipramine, Desipramine, Duloxetine Hydrochloride, Fluoxetine, Imipramine, Mianserin, Nortriptyline, Paroxetine, Sertraline, Triazoles, Venlafaxine Hydrochloride.
- chemical , adverse effects : Amitriptyline, Antidepressive Agents, Citalopram, Clomipramine, Desipramine, Duloxetine Hydrochloride, Fluoxetine, Imipramine, Mianserin, Nortriptyline, Paroxetine, Sertraline, Triazoles, Venlafaxine Hydrochloride.
- chemical , analogs & derivatives : Mianserin.
- drug therapy : Depressive Disorder, Major.
- Adolescent, Bayes Theorem, Child, Confounding Factors (Epidemiology), Double-Blind Method, Drug Administration Schedule, Evidence-Based Medicine, Humans, Randomized Controlled Trials as Topic, Research Design, Treatment Outcome.
Abstract
Major depressive disorder is one of the most common mental disorders in children and adolescents. However, whether to use pharmacological interventions in this population and which drug should be preferred are still matters of controversy. Consequently, we aimed to compare and rank antidepressants and placebo for major depressive disorder in young people.
DOI: 10.1016/S0140-6736(16)30385-3
PubMed: 27289172
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001B32
- to stream PubMed, to step Curation: 001B08
- to stream PubMed, to step Checkpoint: 001B08
Links to Exploration step
pubmed:27289172Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.</title>
<author><name sortKey="Cipriani, Andrea" sort="Cipriani, Andrea" uniqKey="Cipriani A" first="Andrea" last="Cipriani">Andrea Cipriani</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Psychiatry, University of Oxford, Oxford, UK. Electronic address: andrea.cipriani@psych.ox.ac.uk.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Psychiatry, University of Oxford, Oxford</wicri:regionArea>
<placeName><settlement type="city">Oxford</settlement>
<region type="country">Angleterre</region>
<region type="comté" nuts="2">Oxfordshire</region>
<settlement type="city">Oxford</settlement>
</placeName>
<orgName type="university">Université d'Oxford</orgName>
</affiliation>
</author>
<author><name sortKey="Zhou, Xinyu" sort="Zhou, Xinyu" uniqKey="Zhou X" first="Xinyu" last="Zhou">Xinyu Zhou</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing</wicri:regionArea>
<wicri:noRegion>Chongqing</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Del Giovane, Cinzia" sort="Del Giovane, Cinzia" uniqKey="Del Giovane C" first="Cinzia" last="Del Giovane">Cinzia Del Giovane</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena</wicri:regionArea>
<wicri:noRegion>Modena</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hetrick, Sarah E" sort="Hetrick, Sarah E" uniqKey="Hetrick S" first="Sarah E" last="Hetrick">Sarah E. Hetrick</name>
<affiliation wicri:level="4"><nlm:affiliation>Orygen, The National Centre of Excellence in Youth Mental Health, University of Melbourne, Melbourne, VIC, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Orygen, The National Centre of Excellence in Youth Mental Health, University of Melbourne, Melbourne, VIC</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Qin, Bin" sort="Qin, Bin" uniqKey="Qin B" first="Bin" last="Qin">Bin Qin</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing</wicri:regionArea>
<wicri:noRegion>Chongqing</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Whittington, Craig" sort="Whittington, Craig" uniqKey="Whittington C" first="Craig" last="Whittington">Craig Whittington</name>
<affiliation wicri:level="2"><nlm:affiliation>Doctor Evidence, Santa Monica, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Doctor Evidence, Santa Monica, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Coghill, David" sort="Coghill, David" uniqKey="Coghill D" first="David" last="Coghill">David Coghill</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Neuroscience, School of Medicine, University of Dundee, Dundee, UK; Department of Paediatrics, and Department of Psychiatry, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, VIC, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Division of Neuroscience, School of Medicine, University of Dundee, Dundee, UK; Department of Paediatrics, and Department of Psychiatry, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, VIC</wicri:regionArea>
<wicri:noRegion>VIC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zhang, Yuqing" sort="Zhang, Yuqing" uniqKey="Zhang Y" first="Yuqing" last="Zhang">Yuqing Zhang</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing</wicri:regionArea>
<wicri:noRegion>Chongqing</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hazell, Philip" sort="Hazell, Philip" uniqKey="Hazell P" first="Philip" last="Hazell">Philip Hazell</name>
<affiliation wicri:level="1"><nlm:affiliation>Discipline of Psychiatry, Sydney Medical School, Concord West, NSW, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Discipline of Psychiatry, Sydney Medical School, Concord West, NSW</wicri:regionArea>
<wicri:noRegion>NSW</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Leucht, Stefan" sort="Leucht, Stefan" uniqKey="Leucht S" first="Stefan" last="Leucht">Stefan Leucht</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Psychiatry and Psychotherapy, Technische Universität München, Munich, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Psychiatry and Psychotherapy, Technische Universität München, Munich</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
<settlement type="city">Munich</settlement>
</placeName>
<orgName type="university">Université technique de Munich</orgName>
</affiliation>
</author>
<author><name sortKey="Cuijpers, Pim" sort="Cuijpers, Pim" uniqKey="Cuijpers P" first="Pim" last="Cuijpers">Pim Cuijpers</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Clinical, Neuro- and Developmental Psychology, VU University Amsterdam, Amsterdam, Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Clinical, Neuro- and Developmental Psychology, VU University Amsterdam, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pu, Juncai" sort="Pu, Juncai" uniqKey="Pu J" first="Juncai" last="Pu">Juncai Pu</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing</wicri:regionArea>
<wicri:noRegion>Chongqing</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Cohen, David" sort="Cohen, David" uniqKey="Cohen D" first="David" last="Cohen">David Cohen</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Child and Adolescent Psychiatry, Hôpital Pitié-Salpétrière, Institut des Systèmes Intelligents et Robotiques, Université Pierre et Marie Curie, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Child and Adolescent Psychiatry, Hôpital Pitié-Salpétrière, Institut des Systèmes Intelligents et Robotiques, Université Pierre et Marie Curie, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
<settlement type="city">Paris</settlement>
</placeName>
<orgName type="university">Université Pierre-et-Marie-Curie</orgName>
</affiliation>
</author>
<author><name sortKey="Ravindran, Arun V" sort="Ravindran, Arun V" uniqKey="Ravindran A" first="Arun V" last="Ravindran">Arun V. Ravindran</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Liu, Yiyun" sort="Liu, Yiyun" uniqKey="Liu Y" first="Yiyun" last="Liu">Yiyun Liu</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing</wicri:regionArea>
<wicri:noRegion>Chongqing</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Michael, Kurt D" sort="Michael, Kurt D" uniqKey="Michael K" first="Kurt D" last="Michael">Kurt D. Michael</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Psychology, Appalachian State University, Boone, NC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Psychology, Appalachian State University, Boone, NC</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yang, Lining" sort="Yang, Lining" uniqKey="Yang L" first="Lining" last="Yang">Lining Yang</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing</wicri:regionArea>
<wicri:noRegion>Chongqing</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Liu, Lanxiang" sort="Liu, Lanxiang" uniqKey="Liu L" first="Lanxiang" last="Liu">Lanxiang Liu</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing</wicri:regionArea>
<wicri:noRegion>Chongqing</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Xie, Peng" sort="Xie, Peng" uniqKey="Xie P" first="Peng" last="Xie">Peng Xie</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing, China; South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia. Electronic address: xiepeng973@126.com.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing, China; South Australian Health and Medical Research Institute, Adelaide, South Australia</wicri:regionArea>
<wicri:noRegion>South Australia</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2016">2016</date>
<idno type="RBID">pubmed:27289172</idno>
<idno type="pmid">27289172</idno>
<idno type="doi">10.1016/S0140-6736(16)30385-3</idno>
<idno type="wicri:Area/PubMed/Corpus">001B32</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001B32</idno>
<idno type="wicri:Area/PubMed/Curation">001B08</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001B08</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001B08</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001B08</idno>
<idno type="wicri:Area/Ncbi/Merge">003688</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.</title>
<author><name sortKey="Cipriani, Andrea" sort="Cipriani, Andrea" uniqKey="Cipriani A" first="Andrea" last="Cipriani">Andrea Cipriani</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Psychiatry, University of Oxford, Oxford, UK. Electronic address: andrea.cipriani@psych.ox.ac.uk.</nlm:affiliation>
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Psychiatry, University of Oxford, Oxford</wicri:regionArea>
<placeName><settlement type="city">Oxford</settlement>
<region type="country">Angleterre</region>
<region type="comté" nuts="2">Oxfordshire</region>
<settlement type="city">Oxford</settlement>
</placeName>
<orgName type="university">Université d'Oxford</orgName>
</affiliation>
</author>
<author><name sortKey="Zhou, Xinyu" sort="Zhou, Xinyu" uniqKey="Zhou X" first="Xinyu" last="Zhou">Xinyu Zhou</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing</wicri:regionArea>
<wicri:noRegion>Chongqing</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Del Giovane, Cinzia" sort="Del Giovane, Cinzia" uniqKey="Del Giovane C" first="Cinzia" last="Del Giovane">Cinzia Del Giovane</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy.</nlm:affiliation>
<country xml:lang="fr">Italie</country>
<wicri:regionArea>Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena</wicri:regionArea>
<wicri:noRegion>Modena</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hetrick, Sarah E" sort="Hetrick, Sarah E" uniqKey="Hetrick S" first="Sarah E" last="Hetrick">Sarah E. Hetrick</name>
<affiliation wicri:level="4"><nlm:affiliation>Orygen, The National Centre of Excellence in Youth Mental Health, University of Melbourne, Melbourne, VIC, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Orygen, The National Centre of Excellence in Youth Mental Health, University of Melbourne, Melbourne, VIC</wicri:regionArea>
<orgName type="university">Université de Melbourne</orgName>
<placeName><settlement type="city">Melbourne</settlement>
<region type="état">Victoria (État)</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Qin, Bin" sort="Qin, Bin" uniqKey="Qin B" first="Bin" last="Qin">Bin Qin</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing</wicri:regionArea>
<wicri:noRegion>Chongqing</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Whittington, Craig" sort="Whittington, Craig" uniqKey="Whittington C" first="Craig" last="Whittington">Craig Whittington</name>
<affiliation wicri:level="2"><nlm:affiliation>Doctor Evidence, Santa Monica, CA, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Doctor Evidence, Santa Monica, CA</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Coghill, David" sort="Coghill, David" uniqKey="Coghill D" first="David" last="Coghill">David Coghill</name>
<affiliation wicri:level="1"><nlm:affiliation>Division of Neuroscience, School of Medicine, University of Dundee, Dundee, UK; Department of Paediatrics, and Department of Psychiatry, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, VIC, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Division of Neuroscience, School of Medicine, University of Dundee, Dundee, UK; Department of Paediatrics, and Department of Psychiatry, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, VIC</wicri:regionArea>
<wicri:noRegion>VIC</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Zhang, Yuqing" sort="Zhang, Yuqing" uniqKey="Zhang Y" first="Yuqing" last="Zhang">Yuqing Zhang</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing</wicri:regionArea>
<wicri:noRegion>Chongqing</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hazell, Philip" sort="Hazell, Philip" uniqKey="Hazell P" first="Philip" last="Hazell">Philip Hazell</name>
<affiliation wicri:level="1"><nlm:affiliation>Discipline of Psychiatry, Sydney Medical School, Concord West, NSW, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Discipline of Psychiatry, Sydney Medical School, Concord West, NSW</wicri:regionArea>
<wicri:noRegion>NSW</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Leucht, Stefan" sort="Leucht, Stefan" uniqKey="Leucht S" first="Stefan" last="Leucht">Stefan Leucht</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Psychiatry and Psychotherapy, Technische Universität München, Munich, Germany.</nlm:affiliation>
<country xml:lang="fr">Allemagne</country>
<wicri:regionArea>Department of Psychiatry and Psychotherapy, Technische Universität München, Munich</wicri:regionArea>
<placeName><region type="land" nuts="1">Bavière</region>
<region type="district" nuts="2">District de Haute-Bavière</region>
<settlement type="city">Munich</settlement>
<settlement type="city">Munich</settlement>
</placeName>
<orgName type="university">Université technique de Munich</orgName>
</affiliation>
</author>
<author><name sortKey="Cuijpers, Pim" sort="Cuijpers, Pim" uniqKey="Cuijpers P" first="Pim" last="Cuijpers">Pim Cuijpers</name>
<affiliation wicri:level="3"><nlm:affiliation>Department of Clinical, Neuro- and Developmental Psychology, VU University Amsterdam, Amsterdam, Netherlands.</nlm:affiliation>
<country xml:lang="fr">Pays-Bas</country>
<wicri:regionArea>Department of Clinical, Neuro- and Developmental Psychology, VU University Amsterdam, Amsterdam</wicri:regionArea>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Pu, Juncai" sort="Pu, Juncai" uniqKey="Pu J" first="Juncai" last="Pu">Juncai Pu</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing</wicri:regionArea>
<wicri:noRegion>Chongqing</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Cohen, David" sort="Cohen, David" uniqKey="Cohen D" first="David" last="Cohen">David Cohen</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Child and Adolescent Psychiatry, Hôpital Pitié-Salpétrière, Institut des Systèmes Intelligents et Robotiques, Université Pierre et Marie Curie, Paris, France.</nlm:affiliation>
<country xml:lang="fr">France</country>
<wicri:regionArea>Department of Child and Adolescent Psychiatry, Hôpital Pitié-Salpétrière, Institut des Systèmes Intelligents et Robotiques, Université Pierre et Marie Curie, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
<settlement type="city">Paris</settlement>
</placeName>
<orgName type="university">Université Pierre-et-Marie-Curie</orgName>
</affiliation>
</author>
<author><name sortKey="Ravindran, Arun V" sort="Ravindran, Arun V" uniqKey="Ravindran A" first="Arun V" last="Ravindran">Arun V. Ravindran</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Liu, Yiyun" sort="Liu, Yiyun" uniqKey="Liu Y" first="Yiyun" last="Liu">Yiyun Liu</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing</wicri:regionArea>
<wicri:noRegion>Chongqing</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Michael, Kurt D" sort="Michael, Kurt D" uniqKey="Michael K" first="Kurt D" last="Michael">Kurt D. Michael</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Psychology, Appalachian State University, Boone, NC, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Psychology, Appalachian State University, Boone, NC</wicri:regionArea>
<placeName><region type="state">Caroline du Nord</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Yang, Lining" sort="Yang, Lining" uniqKey="Yang L" first="Lining" last="Yang">Lining Yang</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing</wicri:regionArea>
<wicri:noRegion>Chongqing</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Liu, Lanxiang" sort="Liu, Lanxiang" uniqKey="Liu L" first="Lanxiang" last="Liu">Lanxiang Liu</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing</wicri:regionArea>
<wicri:noRegion>Chongqing</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Xie, Peng" sort="Xie, Peng" uniqKey="Xie P" first="Peng" last="Xie">Peng Xie</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing, China; South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia. Electronic address: xiepeng973@126.com.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing, China; South Australian Health and Medical Research Institute, Adelaide, South Australia</wicri:regionArea>
<wicri:noRegion>South Australia</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Lancet (London, England)</title>
<idno type="eISSN">1474-547X</idno>
<imprint><date when="2016" type="published">2016</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Amitriptyline (administration & dosage)</term>
<term>Amitriptyline (adverse effects)</term>
<term>Antidepressive Agents (administration & dosage)</term>
<term>Antidepressive Agents (adverse effects)</term>
<term>Bayes Theorem</term>
<term>Child</term>
<term>Citalopram (administration & dosage)</term>
<term>Citalopram (adverse effects)</term>
<term>Clomipramine (administration & dosage)</term>
<term>Clomipramine (adverse effects)</term>
<term>Confounding Factors (Epidemiology)</term>
<term>Depressive Disorder, Major (drug therapy)</term>
<term>Desipramine (administration & dosage)</term>
<term>Desipramine (adverse effects)</term>
<term>Double-Blind Method</term>
<term>Drug Administration Schedule</term>
<term>Duloxetine Hydrochloride (administration & dosage)</term>
<term>Duloxetine Hydrochloride (adverse effects)</term>
<term>Evidence-Based Medicine</term>
<term>Fluoxetine (administration & dosage)</term>
<term>Fluoxetine (adverse effects)</term>
<term>Humans</term>
<term>Imipramine (administration & dosage)</term>
<term>Imipramine (adverse effects)</term>
<term>Mianserin (administration & dosage)</term>
<term>Mianserin (adverse effects)</term>
<term>Mianserin (analogs & derivatives)</term>
<term>Nortriptyline (administration & dosage)</term>
<term>Nortriptyline (adverse effects)</term>
<term>Paroxetine (administration & dosage)</term>
<term>Paroxetine (adverse effects)</term>
<term>Randomized Controlled Trials as Topic</term>
<term>Research Design</term>
<term>Sertraline (administration & dosage)</term>
<term>Sertraline (adverse effects)</term>
<term>Treatment Outcome</term>
<term>Triazoles (administration & dosage)</term>
<term>Triazoles (adverse effects)</term>
<term>Venlafaxine Hydrochloride (administration & dosage)</term>
<term>Venlafaxine Hydrochloride (adverse effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term>
<term>Amitriptyline (administration et posologie)</term>
<term>Amitriptyline (effets indésirables)</term>
<term>Antidépresseurs (administration et posologie)</term>
<term>Antidépresseurs (effets indésirables)</term>
<term>Calendrier d'administration des médicaments</term>
<term>Chlorhydrate de duloxétine (administration et posologie)</term>
<term>Chlorhydrate de duloxétine (effets indésirables)</term>
<term>Chlorhydrate de venlafaxine (administration et posologie)</term>
<term>Chlorhydrate de venlafaxine (effets indésirables)</term>
<term>Citalopram (administration et posologie)</term>
<term>Citalopram (effets indésirables)</term>
<term>Clomipramine (administration et posologie)</term>
<term>Clomipramine (effets indésirables)</term>
<term>Désipramine (administration et posologie)</term>
<term>Désipramine (effets indésirables)</term>
<term>Enfant</term>
<term>Essais contrôlés randomisés comme sujet</term>
<term>Facteurs de confusion (épidémiologie)</term>
<term>Fluoxétine (administration et posologie)</term>
<term>Fluoxétine (effets indésirables)</term>
<term>Humains</term>
<term>Imipramine (administration et posologie)</term>
<term>Imipramine (effets indésirables)</term>
<term>Miansérine (administration et posologie)</term>
<term>Miansérine (analogues et dérivés)</term>
<term>Miansérine (effets indésirables)</term>
<term>Médecine factuelle</term>
<term>Méthode en double aveugle</term>
<term>Nortriptyline (administration et posologie)</term>
<term>Nortriptyline (effets indésirables)</term>
<term>Paroxétine (administration et posologie)</term>
<term>Paroxétine (effets indésirables)</term>
<term>Plan de recherche</term>
<term>Résultat thérapeutique</term>
<term>Sertraline (administration et posologie)</term>
<term>Sertraline (effets indésirables)</term>
<term>Théorème de Bayes</term>
<term>Triazoles (administration et posologie)</term>
<term>Triazoles (effets indésirables)</term>
<term>Trouble dépressif majeur (traitement médicamenteux)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Amitriptyline</term>
<term>Antidepressive Agents</term>
<term>Citalopram</term>
<term>Clomipramine</term>
<term>Desipramine</term>
<term>Duloxetine Hydrochloride</term>
<term>Fluoxetine</term>
<term>Imipramine</term>
<term>Mianserin</term>
<term>Nortriptyline</term>
<term>Paroxetine</term>
<term>Sertraline</term>
<term>Triazoles</term>
<term>Venlafaxine Hydrochloride</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Amitriptyline</term>
<term>Antidepressive Agents</term>
<term>Citalopram</term>
<term>Clomipramine</term>
<term>Desipramine</term>
<term>Duloxetine Hydrochloride</term>
<term>Fluoxetine</term>
<term>Imipramine</term>
<term>Mianserin</term>
<term>Nortriptyline</term>
<term>Paroxetine</term>
<term>Sertraline</term>
<term>Triazoles</term>
<term>Venlafaxine Hydrochloride</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Mianserin</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Amitriptyline</term>
<term>Antidépresseurs</term>
<term>Chlorhydrate de duloxétine</term>
<term>Chlorhydrate de venlafaxine</term>
<term>Citalopram</term>
<term>Clomipramine</term>
<term>Désipramine</term>
<term>Fluoxétine</term>
<term>Imipramine</term>
<term>Miansérine</term>
<term>Nortriptyline</term>
<term>Paroxétine</term>
<term>Sertraline</term>
<term>Triazoles</term>
</keywords>
<keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Miansérine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Depressive Disorder, Major</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Amitriptyline</term>
<term>Antidépresseurs</term>
<term>Chlorhydrate de duloxétine</term>
<term>Chlorhydrate de venlafaxine</term>
<term>Citalopram</term>
<term>Clomipramine</term>
<term>Désipramine</term>
<term>Fluoxétine</term>
<term>Imipramine</term>
<term>Miansérine</term>
<term>Nortriptyline</term>
<term>Paroxétine</term>
<term>Sertraline</term>
<term>Triazoles</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Trouble dépressif majeur</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Bayes Theorem</term>
<term>Child</term>
<term>Confounding Factors (Epidemiology)</term>
<term>Double-Blind Method</term>
<term>Drug Administration Schedule</term>
<term>Evidence-Based Medicine</term>
<term>Humans</term>
<term>Randomized Controlled Trials as Topic</term>
<term>Research Design</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Calendrier d'administration des médicaments</term>
<term>Enfant</term>
<term>Essais contrôlés randomisés comme sujet</term>
<term>Facteurs de confusion (épidémiologie)</term>
<term>Humains</term>
<term>Médecine factuelle</term>
<term>Méthode en double aveugle</term>
<term>Plan de recherche</term>
<term>Résultat thérapeutique</term>
<term>Théorème de Bayes</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Major depressive disorder is one of the most common mental disorders in children and adolescents. However, whether to use pharmacological interventions in this population and which drug should be preferred are still matters of controversy. Consequently, we aimed to compare and rank antidepressants and placebo for major depressive disorder in young people.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27289172</PMID>
<DateCreated><Year>2016</Year>
<Month>09</Month>
<Day>06</Day>
</DateCreated>
<DateCompleted><Year>2016</Year>
<Month>09</Month>
<Day>19</Day>
</DateCompleted>
<DateRevised><Year>2017</Year>
<Month>11</Month>
<Day>12</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-547X</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>388</Volume>
<Issue>10047</Issue>
<PubDate><Year>2016</Year>
<Month>Aug</Month>
<Day>27</Day>
</PubDate>
</JournalIssue>
<Title>Lancet (London, England)</Title>
<ISOAbbreviation>Lancet</ISOAbbreviation>
</Journal>
<ArticleTitle>Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis.</ArticleTitle>
<Pagination><MedlinePgn>881-90</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/S0140-6736(16)30385-3</ELocationID>
<ELocationID EIdType="pii" ValidYN="Y">S0140-6736(16)30385-3</ELocationID>
<Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Major depressive disorder is one of the most common mental disorders in children and adolescents. However, whether to use pharmacological interventions in this population and which drug should be preferred are still matters of controversy. Consequently, we aimed to compare and rank antidepressants and placebo for major depressive disorder in young people.</AbstractText>
<AbstractText Label="METHODS" NlmCategory="METHODS">We did a network meta-analysis to identify both direct and indirect evidence from relevant trials. We searched PubMed, the Cochrane Library, Web of Science, Embase, CINAHL, PsycINFO, LiLACS, regulatory agencies' websites, and international registers for published and unpublished, double-blind randomised controlled trials up to May 31, 2015, for the acute treatment of major depressive disorder in children and adolescents. We included trials of amitriptyline, citalopram, clomipramine, desipramine, duloxetine, escitalopram, fluoxetine, imipramine, mirtazapine, nefazodone, nortriptyline, paroxetine, sertraline, and venlafaxine. Trials recruiting participants with treatment-resistant depression, treatment duration of less than 4 weeks, or an overall sample size of less than ten patients were excluded. We extracted the relevant information from the published reports with a predefined data extraction sheet, and assessed the risk of bias with the Cochrane risk of bias tool. The primary outcomes were efficacy (change in depressive symptoms) and tolerability (discontinuations due to adverse events). We did pair-wise meta-analyses using the random-effects model and then did a random-effects network meta-analysis within a Bayesian framework. We assessed the quality of evidence contributing to each network estimate using the GRADE framework. This study is registered with PROSPERO, number CRD42015016023.</AbstractText>
<AbstractText Label="FINDINGS" NlmCategory="RESULTS">We deemed 34 trials eligible, including 5260 participants and 14 antidepressant treatments. The quality of evidence was rated as very low in most comparisons. For efficacy, only fluoxetine was statistically significantly more effective than placebo (standardised mean difference -0·51, 95% credible interval [CrI] -0·99 to -0·03). In terms of tolerability, fluoxetine was also better than duloxetine (odds ratio [OR] 0·31, 95% CrI 0·13 to 0·95) and imipramine (0·23, 0·04 to 0·78). Patients given imipramine, venlafaxine, and duloxetine had more discontinuations due to adverse events than did those given placebo (5·49, 1·96 to 20·86; 3·19, 1·01 to 18·70; and 2·80, 1·20 to 9·42, respectively). In terms of heterogeneity, the global I(2) values were 33·21% for efficacy and 0% for tolerability.</AbstractText>
<AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">When considering the risk-benefit profile of antidepressants in the acute treatment of major depressive disorder, these drugs do not seem to offer a clear advantage for children and adolescents. Fluoxetine is probably the best option to consider when a pharmacological treatment is indicated.</AbstractText>
<AbstractText Label="FUNDING" NlmCategory="BACKGROUND">National Basic Research Program of China (973 Program).</AbstractText>
<CopyrightInformation>Copyright © 2016 Elsevier Ltd. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cipriani</LastName>
<ForeName>Andrea</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Psychiatry, University of Oxford, Oxford, UK. Electronic address: andrea.cipriani@psych.ox.ac.uk.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zhou</LastName>
<ForeName>Xinyu</ForeName>
<Initials>X</Initials>
<AffiliationInfo><Affiliation>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Del Giovane</LastName>
<ForeName>Cinzia</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Department of Diagnostic, Clinical and Public Health Medicine, University of Modena and Reggio Emilia, Modena, Italy.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hetrick</LastName>
<ForeName>Sarah E</ForeName>
<Initials>SE</Initials>
<AffiliationInfo><Affiliation>Orygen, The National Centre of Excellence in Youth Mental Health, University of Melbourne, Melbourne, VIC, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Qin</LastName>
<ForeName>Bin</ForeName>
<Initials>B</Initials>
<AffiliationInfo><Affiliation>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Whittington</LastName>
<ForeName>Craig</ForeName>
<Initials>C</Initials>
<AffiliationInfo><Affiliation>Doctor Evidence, Santa Monica, CA, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Coghill</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Division of Neuroscience, School of Medicine, University of Dundee, Dundee, UK; Department of Paediatrics, and Department of Psychiatry, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, VIC, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zhang</LastName>
<ForeName>Yuqing</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Hazell</LastName>
<ForeName>Philip</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Discipline of Psychiatry, Sydney Medical School, Concord West, NSW, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Leucht</LastName>
<ForeName>Stefan</ForeName>
<Initials>S</Initials>
<AffiliationInfo><Affiliation>Department of Psychiatry and Psychotherapy, Technische Universität München, Munich, Germany.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cuijpers</LastName>
<ForeName>Pim</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Department of Clinical, Neuro- and Developmental Psychology, VU University Amsterdam, Amsterdam, Netherlands.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Pu</LastName>
<ForeName>Juncai</ForeName>
<Initials>J</Initials>
<AffiliationInfo><Affiliation>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Cohen</LastName>
<ForeName>David</ForeName>
<Initials>D</Initials>
<AffiliationInfo><Affiliation>Department of Child and Adolescent Psychiatry, Hôpital Pitié-Salpétrière, Institut des Systèmes Intelligents et Robotiques, Université Pierre et Marie Curie, Paris, France.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ravindran</LastName>
<ForeName>Arun V</ForeName>
<Initials>AV</Initials>
<AffiliationInfo><Affiliation>Department of Psychiatry, University of Toronto, Toronto, ON, Canada; Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Liu</LastName>
<ForeName>Yiyun</ForeName>
<Initials>Y</Initials>
<AffiliationInfo><Affiliation>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Michael</LastName>
<ForeName>Kurt D</ForeName>
<Initials>KD</Initials>
<AffiliationInfo><Affiliation>Department of Psychology, Appalachian State University, Boone, NC, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Yang</LastName>
<ForeName>Lining</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Liu</LastName>
<ForeName>Lanxiang</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Xie</LastName>
<ForeName>Peng</ForeName>
<Initials>P</Initials>
<AffiliationInfo><Affiliation>Department of Neurology and Psychiatry, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China; Institute of Neuroscience and the Collaborative Innovation Center for Brain Science, Chongqing Medical University, Chongqing, China; South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia. Electronic address: xiepeng973@126.com.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D017418">Meta-Analysis</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2016</Year>
<Month>06</Month>
<Day>08</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>England</Country>
<MedlineTA>Lancet</MedlineTA>
<NlmUniqueID>2985213R</NlmUniqueID>
<ISSNLinking>0140-6736</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000928">Antidepressive Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014230">Triazoles</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>01K63SUP8D</RegistryNumber>
<NameOfSubstance UI="D005473">Fluoxetine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0DHU5B8D6V</RegistryNumber>
<NameOfSubstance UI="D015283">Citalopram</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>1806D8D52K</RegistryNumber>
<NameOfSubstance UI="D000639">Amitriptyline</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>250PJI13LM</RegistryNumber>
<NameOfSubstance UI="D008803">Mianserin</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>41VRH5220H</RegistryNumber>
<NameOfSubstance UI="D017374">Paroxetine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>59H4FCV1TF</RegistryNumber>
<NameOfSubstance UI="C051752">nefazodone</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>7D7RX5A8MO</RegistryNumber>
<NameOfSubstance UI="D000069470">Venlafaxine Hydrochloride</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>9044SC542W</RegistryNumber>
<NameOfSubstance UI="D000068736">Duloxetine Hydrochloride</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>A051Q2099Q</RegistryNumber>
<NameOfSubstance UI="C035133">mirtazapine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>BL03SY4LXB</RegistryNumber>
<NameOfSubstance UI="D009661">Nortriptyline</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>NUV44L116D</RegistryNumber>
<NameOfSubstance UI="D002997">Clomipramine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>OGG85SX4E4</RegistryNumber>
<NameOfSubstance UI="D007099">Imipramine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>QUC7NX6WMB</RegistryNumber>
<NameOfSubstance UI="D020280">Sertraline</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>TG537D343B</RegistryNumber>
<NameOfSubstance UI="D003891">Desipramine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet. 2016 Aug 27;388(10047):844-5</RefSource>
<PMID Version="1">27289173</PMID>
</CommentsCorrections>
<CommentsCorrections RefType="CommentIn"><RefSource>Pediatrics. 2017 Sep;140(3):null</RefSource>
<PMID Version="1">28860137</PMID>
</CommentsCorrections>
</CommentsCorrectionsList>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000639" MajorTopicYN="N">Amitriptyline</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000928" MajorTopicYN="N">Antidepressive Agents</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001499" MajorTopicYN="N">Bayes Theorem</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015283" MajorTopicYN="N">Citalopram</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002997" MajorTopicYN="N">Clomipramine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015986" MajorTopicYN="N">Confounding Factors (Epidemiology)</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003865" MajorTopicYN="N">Depressive Disorder, Major</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003891" MajorTopicYN="N">Desipramine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004334" MajorTopicYN="N">Drug Administration Schedule</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000068736" MajorTopicYN="N">Duloxetine Hydrochloride</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019317" MajorTopicYN="N">Evidence-Based Medicine</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005473" MajorTopicYN="N">Fluoxetine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007099" MajorTopicYN="N">Imipramine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008803" MajorTopicYN="N">Mianserin</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
<QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009661" MajorTopicYN="N">Nortriptyline</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017374" MajorTopicYN="N">Paroxetine</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012107" MajorTopicYN="N">Research Design</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020280" MajorTopicYN="N">Sertraline</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014230" MajorTopicYN="N">Triazoles</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000069470" MajorTopicYN="N">Venlafaxine Hydrochloride</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName>
<QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2016</Year>
<Month>6</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2016</Year>
<Month>6</Month>
<Day>13</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2016</Year>
<Month>9</Month>
<Day>20</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">27289172</ArticleId>
<ArticleId IdType="pii">S0140-6736(16)30385-3</ArticleId>
<ArticleId IdType="doi">10.1016/S0140-6736(16)30385-3</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Allemagne</li>
<li>Australie</li>
<li>Canada</li>
<li>France</li>
<li>Italie</li>
<li>Pays-Bas</li>
<li>Royaume-Uni</li>
<li>République populaire de Chine</li>
<li>États-Unis</li>
</country>
<region><li>Angleterre</li>
<li>Bavière</li>
<li>Californie</li>
<li>Caroline du Nord</li>
<li>District de Haute-Bavière</li>
<li>Hollande-Septentrionale</li>
<li>Ontario</li>
<li>Oxfordshire</li>
<li>Victoria (État)</li>
<li>Île-de-France</li>
</region>
<settlement><li>Amsterdam</li>
<li>Melbourne</li>
<li>Munich</li>
<li>Oxford</li>
<li>Paris</li>
<li>Toronto</li>
</settlement>
<orgName><li>Université Pierre-et-Marie-Curie</li>
<li>Université d'Oxford</li>
<li>Université de Melbourne</li>
<li>Université de Toronto</li>
<li>Université technique de Munich</li>
</orgName>
</list>
<tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Cipriani, Andrea" sort="Cipriani, Andrea" uniqKey="Cipriani A" first="Andrea" last="Cipriani">Andrea Cipriani</name>
</region>
</country>
<country name="République populaire de Chine"><noRegion><name sortKey="Zhou, Xinyu" sort="Zhou, Xinyu" uniqKey="Zhou X" first="Xinyu" last="Zhou">Xinyu Zhou</name>
</noRegion>
<name sortKey="Liu, Lanxiang" sort="Liu, Lanxiang" uniqKey="Liu L" first="Lanxiang" last="Liu">Lanxiang Liu</name>
<name sortKey="Liu, Yiyun" sort="Liu, Yiyun" uniqKey="Liu Y" first="Yiyun" last="Liu">Yiyun Liu</name>
<name sortKey="Pu, Juncai" sort="Pu, Juncai" uniqKey="Pu J" first="Juncai" last="Pu">Juncai Pu</name>
<name sortKey="Qin, Bin" sort="Qin, Bin" uniqKey="Qin B" first="Bin" last="Qin">Bin Qin</name>
<name sortKey="Yang, Lining" sort="Yang, Lining" uniqKey="Yang L" first="Lining" last="Yang">Lining Yang</name>
<name sortKey="Zhang, Yuqing" sort="Zhang, Yuqing" uniqKey="Zhang Y" first="Yuqing" last="Zhang">Yuqing Zhang</name>
</country>
<country name="Italie"><noRegion><name sortKey="Del Giovane, Cinzia" sort="Del Giovane, Cinzia" uniqKey="Del Giovane C" first="Cinzia" last="Del Giovane">Cinzia Del Giovane</name>
</noRegion>
</country>
<country name="Australie"><region name="Victoria (État)"><name sortKey="Hetrick, Sarah E" sort="Hetrick, Sarah E" uniqKey="Hetrick S" first="Sarah E" last="Hetrick">Sarah E. Hetrick</name>
</region>
<name sortKey="Coghill, David" sort="Coghill, David" uniqKey="Coghill D" first="David" last="Coghill">David Coghill</name>
<name sortKey="Hazell, Philip" sort="Hazell, Philip" uniqKey="Hazell P" first="Philip" last="Hazell">Philip Hazell</name>
<name sortKey="Xie, Peng" sort="Xie, Peng" uniqKey="Xie P" first="Peng" last="Xie">Peng Xie</name>
</country>
<country name="États-Unis"><region name="Californie"><name sortKey="Whittington, Craig" sort="Whittington, Craig" uniqKey="Whittington C" first="Craig" last="Whittington">Craig Whittington</name>
</region>
<name sortKey="Michael, Kurt D" sort="Michael, Kurt D" uniqKey="Michael K" first="Kurt D" last="Michael">Kurt D. Michael</name>
</country>
<country name="Allemagne"><region name="Bavière"><name sortKey="Leucht, Stefan" sort="Leucht, Stefan" uniqKey="Leucht S" first="Stefan" last="Leucht">Stefan Leucht</name>
</region>
</country>
<country name="Pays-Bas"><region name="Hollande-Septentrionale"><name sortKey="Cuijpers, Pim" sort="Cuijpers, Pim" uniqKey="Cuijpers P" first="Pim" last="Cuijpers">Pim Cuijpers</name>
</region>
</country>
<country name="France"><region name="Île-de-France"><name sortKey="Cohen, David" sort="Cohen, David" uniqKey="Cohen D" first="David" last="Cohen">David Cohen</name>
</region>
</country>
<country name="Canada"><region name="Ontario"><name sortKey="Ravindran, Arun V" sort="Ravindran, Arun V" uniqKey="Ravindran A" first="Arun V" last="Ravindran">Arun V. Ravindran</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Ncbi/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003688 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd -nk 003688 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Asie |area= AustralieFrV1 |flux= Ncbi |étape= Merge |type= RBID |clé= pubmed:27289172 |texte= Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Merge/RBID.i -Sk "pubmed:27289172" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Merge/biblio.hfd \ | NlmPubMed2Wicri -a AustralieFrV1
![]() | This area was generated with Dilib version V0.6.33. | ![]() |